Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05764564
Other study ID # Pro00112081
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date April 21, 2023
Est. completion date January 1, 2025

Study information

Verified date April 2024
Source Duke University
Contact Marat Fudim
Phone 9196815816
Email marat.fudim@duke.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the study is to test the impact of positive and negative body pressure on exercise capacity, symptoms, blood volume distribution and central cardiac hemodynamics in patients with heart failure and preserved ejection fraction. Aim 1 will study healthy volunteers and heart failure patients non invasively while Aim 2 will study heart failure patients invasively (intracardiac pressures).


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date January 1, 2025
Est. primary completion date January 1, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years and older
Eligibility - Heart Failure Study Population - Inclusion Criteria (Aim 1 and 2): - Age greater than or equal to 30 yrs - Established diagnosis of HFpEF with left ventricular ejection fraction greater than or equal to 50% - NYHA II-III symptoms - Stable HF drug regimen for the preceding 1 month - Wedge pressure greater than or equal to 15 mmHg at rest or greater than or equal to 25 mmHg with peak exercise - (For Aim 2 only) Scheduled for an elective right heart catheterization at Duke University Hospital. - Exclusion Criteria (Aim 1 and 2): - HF hospitalization for type I myocardial infarction within 3 months - Infiltrative (ie amyloid) or hypertrophic cardiomyopathy - Uncontrolled atrial or ventricular arrhythmia - Chronic oxygen use - History of vasovagal syncope - Considered inappropriate to participate by PI or Sub-I - Healthy Volunteers (Controls) - Inclusion Criteria (Aim 1): - Age greater than or equal to 30 yrs - Able to speak English - Ambulatory [assistive devices ok] - Able to provide informed consent - Exclusion Criteria (Aim 1): - Acute myocardial infarction (3-5 days) - Unstable angina - Uncontrolled arrhythmia causing symptoms or haemodynamic compromise - Syncope - Active endocarditis - Acute myocarditis or pericarditis - Symptomatic severe aortic aneurysm - Uncontrolled asthma - Arterial desaturation at rest on room air <85% - Untreated left main stem coronary stenosis - Asymptomatic severe aortic stenosis - Severe untreated arterial hypertension at rest (>200 mm Hg systolic, >120 mm Hg diastolic) - Tachyarrhythmias or bradyarrhythmias - Hypertrophic cardiomyopathy - Significant pulmonary hypertension - Thrombosis of the lower extremity until treated for a minimum of 2 weeks - Within 2 weeks of acute symptomatic pulmonary embolus - Abdominal aortic aneurysm >8.0 cm - Electrolyte abnormalities - Pregnancy - Inmate of correctional facility (i.e. prisoner) - Diagnosed history of dementia - Inability to ambulate independently - Considered inappropriate to participate by Principal Investigator

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Positive or negative pressure
Positive or negative pressure is applied via a closed chamber.

Locations

Country Name City State
United States Duke University Medical Center Durham North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Duke University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Symptom burden from rest to peak exertion we will assess symptom burden with dyspnea scales Day 1
Primary change in exercise cardiac output Change in cardiac output from rest to 0 Watts exercise Day 1
Secondary change in exercise cardiac output Change in cardiac output from rest to 20 Watts exercise Day 1
Secondary change in heart rate Change in heart rate from rest to 0 Watts exercise Day 1
Secondary change in heart rate Change in heart rate from rest to 20 Watts exercise Day 1
Secondary change in respiratory rate Change in heart rate from rest to 20 Watts exercise Day 1
Secondary change in O2 consumption Change in O2 consumption from rest to 0 Watts exercise Day 1
Secondary change in O2 consumption Change in O2 consumption from rest to 20 Watts exercise Day 1
Secondary Change in wedge pressure Change in wedge pressure from rest to 0 Watts exercise Day 1
Secondary Change in wedge pressure Change in wedge pressure from rest to 20 Watts exercise Day 1
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04573166 - Personalized Atrial Septostomy for Heart Failure N/A
Recruiting NCT02425371 - Optimized Management of Comorbidity in Heart Failure With Preserved Ejection Fraction in the Elderly (>60 Years) Phase 3
Terminated NCT03312387 - Muscle, Essential Amino Acids, and eXercise in Heart Failure N/A
Completed NCT05475028 - Network Medicine Approaches to Classify Heart Failure With PReserved Ejection Fraction by Signatures of DNA Methylation and Point-of-carE Risk calculaTors (PRESMET)
Recruiting NCT04950218 - The Psoriasis Echo Study
Completed NCT02334891 - Kyoto Congestive Heart Failure Study
Recruiting NCT05577819 - Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF N/A
Completed NCT05139472 - Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction Phase 3
Recruiting NCT04682704 - The Effect of Different Low-Level Tragus Stimulation Parameters On Autonomic Nervous System Function N/A
Completed NCT03924479 - Respiratory Muscle Function in Heart Failure N/A
Recruiting NCT03830957 - Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker N/A
Completed NCT02589977 - Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Phase 4
Completed NCT02946476 - Prognostic Impact of Noncardiac Comorbidities in Heart Failure Patients N/A
Recruiting NCT04179643 - NAN-101 in Patients With Class III Heart Failure Phase 1
Recruiting NCT05425459 - RESPONDER-HF Trial N/A
Completed NCT04940312 - MyoMobile Study: App-based Activity Coaching in Patients With Heart Failure and Preserved Ejection Fraction
Recruiting NCT04602338 - Diagnosis and OutcoMes evaluAtIoN of Multicenter Patients With HFpEF Using Multimodality Imaging
Completed NCT03240237 - CCM in Heart Failure With Preserved Ejection Fraction N/A
Recruiting NCT05887271 - A Randomised, Controlled Trial of a Low-energy Diet for Improving Functional Status in Heart Failure With PRESERVED Ejection Fraction Preserved Ejection Fraction Phase 2/Phase 3
Recruiting NCT05479669 - Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction